Compare Bristol-Myers Squibb Co (BMY) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs New York Times Co — how do they compare? Bristol-Myers Squibb Co trades at $58.61 (market cap $116.30B), while New York Times Co trades at $75.24 (market cap $11.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.8× New York Times Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NYT | |
|---|---|---|
Market Cap | $116.30B | $11.81B |
Sector | Health | Media |
52-Week High | $62.37 | $85.86 |
52-Week Low | $42.60 | $51.43 |
Enterprise Value | $152.24B | $11.21B |
Dividend Yield | 4.42% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
The New York Times (NYT) stock trades at $75.04, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with revenue growth from $2.3B in 2022 to $2.8B in 2025 and net income margin improving to 12.17%. Recent earnings beats and a 29.41% analyst buy rating support positive sentiment, though legal and regulatory pressures from ongoing subpoenas and copyright disputes with OpenAI present near-term risks.
Outlook remains cautiously optimistic with a consensus price target of $78.00, offering ~4% upside. Investment opportunities include consistent earnings growth and defensive stock characteristics amid market volatility. Key risks involve legal overhangs from government subpoenas and AI copyright litigation, which could impact operational focus and financial performance if prolonged.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
